Vasculitis & polymyalgia rheumatica
Clinical outcomes of upadacitinib continuation vs withdrawal in giant cell arteritis through 2 years
Authors' conclusion
These data further support a favourable benefit-risk profile for extended use of upadacitinib 15 mg for treatment of GCA.
Study context
- Population
- Patients with giant cell arteritis (GCA) aged ≥50 years on upadacitinib 15 mg achieving ≥24 weeks of consecutive remission by week 52 in SELECT-GCAre-randomised 2:1 in period 2
- Participants
- 103 patients
- Comparison
- Upadacitinib 15 mg continuation vs switch to placebo at week 52
- Upadacitinib 15 mgn = 68
- Placebon = 35reference
Methodological detailsre-randomised, blinded extension
- Re-randomised
- Blinded extension
Primary result
As reported in the abstract
Disease flares · weeks 52 to 104
P ≤ 0.0001
Further findings
Maintenance of GC-free remission · weeks 52 to 104 · All P values are nominal
P ≤ 0.0001
GC exposure · weeks 52 to 104 · All P values are nominal
P ≤ 0.0001
Safety
- Safety generally similar between upadacitinib and placebo; no new clinically significant safety risks through 2 years
Original publication
Clinical outcomes of upadacitinib continuation vs withdrawal in giant cell arteritis through 2 years. Ann Rheum Dis. Published 28 July 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →